Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment.

ABSTRACT:

Objective

To evaluate the efficacy and safety of minocycline in the management of HIV-associated cognitive impairment.

Methods

We enrolled HIV-positive participants with a CD4 count of 250 to 500 cells/μL in a randomized, double-blind, placebo-controlled study. They received 100 mg of minocycline or matching placebo orally every 12 hours for 24 weeks. Cognitive function was measured using the Uganda neuropsychological test battery summary measure (U NP Sum) and the Memorial Sloan-Kettering (MSK) scale. The primary efficacy measure was the 24-week change in an average of 9 standardized U NP Sum z scores.

Results

Seventy-three participants were enrolled. Of these, 90% were female, 49% were between the ages 30 and 39 years, and 74% had 6 or more years of education. One p

SUBMITTER: Nakasujja N 

PROVIDER: S-EPMC3589188 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature